Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Time to Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $17.89, but opened at $16.83. Daiichi Sankyo shares last traded at $16.66, with a volume of 2,134 shares traded.

Wall Street Analysts Forecast Growth

DSNKY has been the subject of a number of research analyst reports. Zacks Research lowered shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Daiichi Sankyo has an average rating of “Reduce”.

Daiichi Sankyo Price Performance

The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.96 and a current ratio of 2.92. The firm has a market cap of $30.79 billion, a P/E ratio of 19.22, a P/E/G ratio of 1.90 and a beta of -0.11. The company has a 50-day moving average of $17.82 and a 200 day moving average of $17.79.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. On average, sell-side analysts anticipate that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.